Post-bariatric Hypglycemia

Home»Post-bariatric Hypglycemia
17 10, 2016

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)

2017-02-07T17:19:37+00:00

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) PALO ALTO, Calif., October 17, 2016 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to [...]

Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)2017-02-07T17:19:37+00:00
13 06, 2016

Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia

2017-02-07T18:08:57+00:00

Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia Oral Presentation at American Diabetes Association Meeting in New Orleans, LA PALO ALTO, Calif., June 13, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, [...]

Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia2017-02-07T18:08:57+00:00
10 05, 2016

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery

2017-02-07T18:12:44+00:00

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery Novel first-in-class GLP-1 antagonist targeted for rare hypoglycemic condition PALO ALTO, Calif., May 10, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies [...]

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery2017-02-07T18:12:44+00:00
12 11, 2015

Eiger Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University

2017-02-07T18:46:01+00:00

Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University - Clinical Proof of Concept Data Already Generated in Patients PALO ALTO, Calif., November 12, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to a targeted therapeutic for treating post-bariatric surgical hypoglycemia.  [...]

Eiger Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University2017-02-07T18:46:01+00:00